Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-04-19
Based on 371 first isolates · MED-B · Febrile UTI / pyelonephritis · 2025-04-20 → 2026-04-19
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 80 % (76 %–84 %)
Not covered: Enterococcus faecalis (8 %), Escherichia coli (5 %), Staphylococcus aureus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
88 %
92 %
n = 36
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
83 %
n = 36
nitrofurantoin NIT
trend · Escherichia coli not for this site
82 %
83 %
n = 36
ceftriaxone CRO
trend · Escherichia coli
81 %
89 %
n = 36
mecillinam MEC
trend · Escherichia coli not for this site
80 %
86 %
n = 36
ciprofloxacin CIP
trend · Escherichia coli
80 %
81 %
n = 36
75 %
72 %
n = 36
trimethoprim TMP
trend · Escherichia coli not for this site
72 %
81 %
n = 36
45 %
47 %
n = 36
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
10 %
8 %
n = 36
4 %
3 %
n = 36
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
0 %
n = 36

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Citrobacter freundii
4 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.